To date ipilimumab and tremelimumab are the two anti-CTLA-4 agents approved for use in advanced cancer and among them, tremelimumab was the first immune checkpoint inhibitor to be tested in HCC [21]. Here, CTLA4 is linked to hepatocellular carcinoma.